Peter Hillmen, the modern father of this field, presents the treatment of thrombosis and thrombotic complications in patients with paroxysmal nocturnal hemoglobinuria (PNH).
A combination of 4 novel urine biomarkers achieved a specificity and positive predictive value for prostate cancer that was more accurate than the PSA and the PCA3. Medscape Medical News
In this Expert Interview from ASH 2007, Dr. Jorge Cortes discusses new and follow-up data from clinical trials of drug therapies for CML. Medscape Hematology-Oncology
Dr. Anita Hill, who specializes in paroxysmal nocturnal hemoglobinuria (PNH) and in marrow failure, discusses the effects on quality of life of new therapies.
Estrogens behave as protective agents on the development of colorectal cancer, and hormonal-replacement therapy is associated with an increased survival rate in women with this disease. Expert Review of Endocrinology and Metabolism